Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Daniel Alvarez-Gomez"'
Autor:
María Jose Rebollo-Lopez, Joël Lelièvre, Daniel Alvarez-Gomez, Julia Castro-Pichel, Francisco Martínez-Jiménez, George Papadatos, Vinod Kumar, Gonzalo Colmenarejo, Grace Mugumbate, Mark Hurle, Vanessa Barroso, Rob J Young, María Martinez-Hoyos, Rubén González del Río, Robert H Bates, Eva Maria Lopez-Roman, Alfonso Mendoza-Losana, James R Brown, Emilio Alvarez-Ruiz, Marc A Marti-Renom, John P Overington, Nicholas Cammack, Lluís Ballell, David Barros-Aguire
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0142293 (2015)
As a follow up to the antimycobacterial screening exercise and the release of GSK´s first Tres Cantos Antimycobacterial Set (TCAMS-TB), this paper presents the results of a second antitubercular screening effort of two hundred and fifty thousand com
Externí odkaz:
https://doaj.org/article/8e46eddd23e54015ab4639bb3308df5d
Autor:
David Barros, Robert J. Young, Roman Šink, Chun-wa Chung, Matej Živec, Daniel Alvarez-Gomez, Emilio Alvarez-Ruiz, Lourdes Encinas, Esther Pérez-Herrán, María Martínez-Hoyos, Stanislav Gobec, Julia Castro-Pichel, Stane Pajk, Alfonso Mendoza-Losana, Margarete Neu, Izidor Sosič, Máire A. Convery, Lluís Ballell-Pages
Publikováno v:
European Journal of Medicinal Chemistry. 112:252-257
Tetrahydropyran derivative 1 was discovered in a high-throughput screening campaign to find new inhibitors of mycobacterial InhA. Following initial in-vitro profiling, a structure-activity relationship study was initiated and a focused library of ana
Autor:
Lluis Ballell, Daniel Alvarez-Gomez, Siddharth Malik, Uday Chandra Kumar, Prashanta Kumar-Sahu, Sarma Jarp, Dharmarajan Sriram, S. K. Mahmood, Suneel Kumar Bvs, Sridevi Pulakanam
Publikováno v:
Future Medicinal Chemistry. 5:249-259
Background: InhA is a promising and attractive target in antimycobacterial drug development. InhA is involved in the reduction of long-chain trans-2-enoyl-ACP in the type II fatty acid biosynthesis pathway of Mycobacterium tuberculosis. Recent studie
Autor:
Roman Šink, Joaquin Rullas-Triconado, Lluís Ballell-Pages, Eva Maria Lopez-Roman, Robert J. Young, Lourdes Encinas, David Barros, Raquel Fernandez-Menendez, Samo Turk, Matej Živec, Stane Pajk, Izidor Sosič, Stanislav Gobec, Iñigo Angulo-Barturen, Daniel Alvarez-Gomez, Carolina Gonzales-Cortez
Publikováno v:
Journal of medicinal chemistry. 58(2)
Mycobacterial enoyl acyl carrier protein reductase (InhA) is a clinically validated target for the treatment of tuberculosis infections, a disease that still causes the death of at least a million people annually. A known class of potent, direct, and
Autor:
María Martínez-Hoyos, Esther Perez-Herran, Gulcin Gulten, Lourdes Encinas, Daniel Álvarez-Gómez, Emilio Alvarez, Santiago Ferrer-Bazaga, Adolfo García-Pérez, Fátima Ortega, Iñigo Angulo-Barturen, Joaquin Rullas-Trincado, Delia Blanco Ruano, Pedro Torres, Pablo Castañeda, Sophie Huss, Raquel Fernández Menéndez, Silvia González del Valle, Lluis Ballell, David Barros, Sundip Modha, Neeraj Dhar, François Signorino-Gelo, John D. McKinney, Jose Francisco García-Bustos, Jose Luis Lavandera, James C. Sacchettini, M. Soledad Jimenez, Nuria Martín-Casabona, Julia Castro-Pichel, Alfonso Mendoza-Losana
Publikováno v:
EBioMedicine, Vol 8, Iss C, Pp 291-301 (2016)
Despite being one of the first antitubercular agents identified, isoniazid (INH) is still the most prescribed drug for prophylaxis and tuberculosis (TB) treatment and, together with rifampicin, the pillars of current chemotherapy. A high percentage o
Externí odkaz:
https://doaj.org/article/24f2b3c2204144699909714a57e27a13